{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:28:30Z","timestamp":1788881310460,"version":"build-2803163510"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To provide an overview of recent discoveries related to myositis-specific autoantibodies (MSAs) and assays used for their measurement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>New autoantibody specificities have been reported including a MSA directed against eukaryotic initiation factor 3 and a myositis-associated autoantibody directed against heat shock factor 1. The association of anti-TIF1\u03b3 with cancer-associated dermatomyositis dependent on age has been confirmed in several large cohorts. Despite MSAs being almost entirely mutually exclusive, several myositis autoantigens are overexpressed in regenerating muscle and do not correlate with the corresponding MSA in any one patient. Further mechanisms may determine the final MSA specificity and are likely to include the need for autoantigen processing and presentation with adaptive T-cell help. The presence of CD4-positive T cells specific for histidyl tRNA synthetase protein in bronchial lavage fluid from antisynthetase patients lends support to this view. Finally, it is widely held that MSA do play an important role in clinical practice among some evidence and concern about commercial assay reliability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>MSAs continue to provide important tools for clinical diagnosis and management as well as insights into disease mechanisms. Further improvement in the standardization and reliability of routine detection of MSAs is a high priority.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000742","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T21:08:01Z","timestamp":1599253681000},"page":"548-552","source":"Crossref","is-referenced-by-count":15,"title":["Myositis autoantibodies: recent perspectives"],"prefix":"10.1097","volume":"32","author":[{"given":"Victoria","family":"Riddell","sequence":"first","affiliation":[{"name":"Department of Biology and Biochemistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bagby","sequence":"additional","affiliation":[{"name":"Department of Biology and Biochemistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"McHugh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmacology, University of Bath, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/rheumatology\/kez406","article-title":"Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis","volume":"59","author":"Betteridge","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R5-20230829","article-title":"Identification of a novel autoantibody against heat shock factor 1 in idiopathic inflammatory myopathy","author":"Zhang","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s10067-018-4031-4","article-title":"The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy","volume":"37","author":"Zhang","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/annrheumdis-2015-207509","article-title":"PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjogren's syndrome","volume":"75","author":"Fiorentino","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/rheumatology\/ker408","article-title":"Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM\/interstitial lung disease during disease remission","volume":"51","author":"Muro","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1684\/ejd.2019.3634","article-title":"Clinical features and poor prognostic factors of antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease","volume":"29","author":"Motegi","year":"2019","journal-title":"Eur J Dermatol"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of antip155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Araguas","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/key357","article-title":"The temporal relationship between cancer and adult onset antitranscriptional intermediary factor 1 antibody-positive dermatomyositis","volume":"58","author":"Oldroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R14-20230829","first-page":"67","article-title":"Antitranscriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study","volume":"38","author":"Dani","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/art.40895","article-title":"The IgG2 isotype of anti-transcription intermediary factor 1\u03b3 autoantibodies is a biomarker of cancer and mortality in adult dermatomyositis","volume":"71","author":"Aussy","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/bjd.17098","article-title":"Autoantibody to transcriptional intermediary factor-1beta as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy","volume":"180","author":"Ueda-Hayakawa","year":"2019","journal-title":"Br J Dermatol"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/art.33402","article-title":"Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection","volume":"64","author":"Fiorentino","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/art.40883","article-title":"Myositis autoantigen expression correlates with muscle regeneration but not autoantibody specificity","volume":"71","author":"Pinal-Fernandez","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/art.41075","article-title":"Proinflammatory histidyl-transfer RNA synthetase-specific CD4+ T cells in the blood and lungs of patients with idiopathic inflammatory myopathies","volume":"72","author":"Galindo-Feria","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R21-20230829","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217522","article-title":"Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis","author":"Megremis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13075-020-02210-2","article-title":"The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis","volume":"22","author":"Tansley","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/annrheumdis-2018-214690","article-title":"Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies","volume":"78","author":"Espinosa-Ortega","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pathol.2016.03.012","article-title":"Diagnostic performance of a commercial immunoblot assay for myositis antibody testing","volume":"48","author":"Bundell","year":"2016","journal-title":"Pathology"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.41088","article-title":"Myositis autoantibodies: a comparison of results from the Oklahoma Medical Research Foundation myositis panel to the Euroimmun Research Line Blot","volume":"72","author":"Mecoli","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3389\/fimmu.2019.00848","article-title":"Comparison of three immunoassays for the detection of myositis specific antibodies","volume":"10","author":"Mahler","year":"2019","journal-title":"Front Immunol"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamaneurol.2017.0934","article-title":"Skeletal muscle involvement in antisynthetase syndrome","volume":"74","author":"Noguchi","year":"2017","journal-title":"JAMA Neurol"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","article-title":"Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera","volume":"433","author":"Cavazzana","year":"2016","journal-title":"J Immunol Methods"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/14397595.2016.1213947","article-title":"Comparison of anti-OJ antibody detection assays between an immunoprecipitation assay and line blot assay","volume":"27","author":"Hamaguchi","year":"2017","journal-title":"Mod Rheumatol"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"e85062","DOI":"10.1371\/journal.pone.0085062","article-title":"The multicenter study of a new assay for simultaneous detection of multiple antiaminoacyl-tRNA synthetases in myositis and interstitial pneumonia","volume":"9","author":"Nakashima","year":"2014","journal-title":"PLoS One"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.autrev.2019.05.002","article-title":"Anti-OJ autoantibodies: rare or underdetected?","volume":"18","author":"Vulsteke","year":"2019","journal-title":"Autoimmun Rev"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kD protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/1756-185X.13449","article-title":"A case of cancer-associated myositis with anti-Mi-2 antibody: false-positive antitranscriptional intermediary factor 1-\u03b3 antibody by commercial enzyme-linked immunosorbent assay","volume":"22","author":"Nawata","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.41228","article-title":"Clinical significance of higher cutoffs for myositis autoantibody positivity using the Euroimmun Research Line Blot: comment on the article by Mecoli et al","volume":"75","author":"Zampeli","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"112661","DOI":"10.1016\/j.jim.2019.112661","article-title":"Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies","volume":"474","author":"Cavazzana","year":"2019","journal-title":"J Immunol Methods"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/rheumatology\/kez092","article-title":"Autoantibodies to Mi-2 alpha and Mi-2 beta in patients with idiopathic inflammatory myopathy","volume":"58","author":"Richards","year":"2019","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T07:14:19Z","timestamp":1693293259000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000742","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]}}}